Loading
JAB 21822 / Non Small Cell Lung Cancer · Phase 1/2 Trial
ClinicalTrials.gov · August 13, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a clinical trial registration for a Phase 1/2 study of JAB-21822 in patients with KRAS p.G12C-mutant and STK11 co-mutant NSCLC. The study is currently recruiting and has not yet reported results. The registry record specifies primary outcome measures (DLTs, adverse events, and objective response rate) but contains no efficacy or safety data.
Phase 1/2, Interventional, Non Randomized, Sequential, Open label, Treatment purpose. Non-small Cell Lung Cancer; age from 18 Years. Intervention: Phase 1 ,Dose Exploration ,monotherapy; Phase 2, Dose Expansion, Part1 monotherapy; Phase 2 Dose Expansion, Part 2 monotherapy. n = 104. 21 sites: China.
This is a clinical trial registration for a Phase 1/2 study of JAB-21822 in patients with KRAS p.G12C-mutant and STK11 co-mutant NSCLC. The study is currently recruiting and has not yet reported results. The registry record specifies primary outcome measures (DLTs, adverse events, and objective response rate) but contains no efficacy or safety data.
Study is still recruiting; no interim or final data on safety or efficacy are available.
No clinical impact can be assessed from this registry record, as no results have been reported. Clinicians should await publication of safety, tolerability, and efficacy data before considering this agent for clinical use.
This is a Phase 1/2 trial registration with no results posted; it describes planned enrollment and primary outcome measures but reports no clinical data, efficacy, or safety findings.
As stated by the source record.
Quoted from the source exactly as published.
No clinical impact can be assessed from this registry record, as no results have been reported. Clinicians should await publication of safety, tolerability, and efficacy data before considering this agent for clinical use.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05276726). This is a study registration, not published results. Lead sponsor: Allist Pharmaceuticals, Inc.. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 104 participants (ESTIMATED). Conditions: Non-small Cell Lung Cancer. Interventions: DRUG: JAB 21822. Primary outcome measures: Dose Escalation phase Number of participants with dose limiting toxicities (DLTs) , At the end of Cycle 1 (each cycle is 21 days); Dose Escalation phase: Number of participants with adverse events , Up to 3 years; Dose Expansion phase: Objective response rate (ORR) , Up to 3 years - from baseline to confirmed Progressive Disease per RECIST.. Brief summary: Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.